Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03818178 · ClinicalTrials.gov registry record · NA

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

A NA study of Insulin Resistance, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT03818178: Recruiting NA study of Insulin Resistance, sponsored by Mayo Clinic.

NCT03818178 is a NA study of Insulin Resistance that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03818178, a NA study of Insulin Resistance, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours. The investigators do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. The investigators propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an overnight, intra-duodenal palm oil infusion vs. an overnight intra-duodenal Intralipid infusion (both compared to saline control). The investigators will compare the muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates, providing the first measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the whole body and cellular/molecular levels. By identifying which steps in the insulin signaling pathway are most affected, the investigators will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance. Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into intra-myocellular ceramides and abnormal insulin signaling. Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into intra-myocellular saturated DG and abnormal insulin signaling.

Conditions Studied

Interventions

  • OTHER Saline
  • DIETARY_SUPPLEMENT Intralipid
  • DIETARY_SUPPLEMENT Palm Oil Emulsion

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-12-01
Est. Completion 2026-12
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03818178

The ClinicalTrials.gov registry entry for NCT03818178 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (76% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.

NCT03818178 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03818178 about?

NCT03818178 is a clinical study titled "Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids". Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with In...

What is the current status of trial NCT03818178?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-12-01. Estimated completion is 2026-12.

What conditions does trial NCT03818178 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT03818178?

The interventions under investigation include: Saline (OTHER), Intralipid (DIETARY_SUPPLEMENT), Palm Oil Emulsion (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03818178?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03818178 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.